» Articles » PMID: 23529013

Salivary Proteomic Analysis and Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Overview
Date 2013 Mar 27
PMID 23529013
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Graft-versus-host disease (GVHD) is the major life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), developing in 35%-70% of all allo-HSCT recipients despite immunosuppressive prophylaxis. The recent application of proteomic tools that allow screening for differentially expressed or excreted proteins in body fluids could possibly identify specific biomarkers for GVHD. Whole saliva is highly attractive for noninvasive specimen collection. In the present study, we collected saliva specimens from 40 consecutives patients who underwent allo-HSCT between December 2008 and March 2011 at our institution. The specimens were analyzed by HPLC coupled to electrospray-ionization mass spectrometry. Variable expression of S100 protein family members (S100A8, S100A9, and S100A7) was detected. Fourteen of 23 patients with GVHD demonstrated the presence of S100A8, compared with only 2 patients without GVHD and 0 patients in the control group (P = .001). S100A7 was detectable in 11 of the 23 patients with GVHD but was absent in the other 2 groups (P = .0001). S100A9-short was detected in 20 patients with GVHD, in 9 patients without GVHD, and in 8 healthy volunteers (P = .01) Further studies are needed to clarify the role of these proteins as a marker of GVHD or as an index of mucosal inflammation.

Citing Articles

Inflammasomes: potential therapeutic targets in hematopoietic stem cell transplantation.

Luo J, Zhou Y, Wang M, Zhang J, Jiang E Cell Commun Signal. 2024; 22(1):596.

PMID: 39695742 PMC: 11657697. DOI: 10.1186/s12964-024-01974-3.


Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?.

Alexoudi V, Gavriilaki E, Cheva A, Sakellari I, Papadopoulou S, Paraskevopoulos K Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543084 PMC: 10975293. DOI: 10.3390/ph17030298.


Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.

Iacobescu M, Pop C, Uifalean A, Mogosan C, Cenariu D, Zdrenghea M Front Immunol. 2024; 15:1327035.

PMID: 38433830 PMC: 10904603. DOI: 10.3389/fimmu.2024.1327035.


Assessment of the Salivary Concentrations of Selected Immunological Components in Adult Patients in the Late Period after Allogeneic Hematopoietic Stem Cell Transplantation-A Translational Study.

Brodzikowska A, Kochanska B, Boguslawska-Kapala A, Struzycka I, Gorski B, Miskiewicz A Int J Mol Sci. 2024; 25(3).

PMID: 38338734 PMC: 10855433. DOI: 10.3390/ijms25031457.


Single-cell clonal tracking of persistent T-cells in allogeneic hematopoietic stem cell transplantation.

Obermayer B, Keilholz L, Conrad T, Frentsch M, Blau I, Vuong L Front Immunol. 2023; 14:1114368.

PMID: 36860867 PMC: 9969884. DOI: 10.3389/fimmu.2023.1114368.